Clinical Trials

Carcinoma, Non-Small-Cell Lung, Hereditary Sensory and Autonomic Neuropathies

NCT06161441 2026-05-28

A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery

195 enrolled

Resectable Non-small Cell Lung Cancer

NCT06508463 2026-05-28

Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma

Phase 1 Recruiting

21 enrolled

Lymphoid

Mycosis Fungoides, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic

NCT07404332 2026-05-28

5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors

Phase 1 Recruiting

35 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT06900595 2026-05-22

Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer

48 enrolled

Endocrine

Adrenocortical Carcinoma

NCT07281417 2026-05-22

Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma

108 enrolled

Sinonasal Squamous Cell Carcinoma

NCT07603856 2026-05-22

REVIVE

39 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06448026 2026-05-20

Cemiplimab and Cetuximab Prior Salvage Surgery in Patients With Recurrent Oral Cavity Squamous Cell Carcinoma (OCSCC).

17 enrolled

Mouth Neoplasms

NCT06787612 2026-05-20

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

220 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06855212 2026-05-20

Phase II Study of Neoadjuvant Cetuximab and Cemiplimab in Patients Undergoing Surgery for HNSCC

22 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT06860815 2026-05-20

Cemiplimab and Transarterial Radioembolization With Y-90 SIR-S Spheres for the Treatment of Liver Directed Metastatic Breast Cancer

11 enrolled

Breast

Breast Neoplasms

NCT07195734 2026-05-19

Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer

180 enrolled

789 enrolled 32 charts 1 FDA

Carcinoma, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT03409614 2026-05-18

Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer

Phase 3 Completed

Phase 1/2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07594106 2026-05-18

REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma

265 enrolled

Carcinoma, Renal Cell

NCT05574101 2026-05-15

A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer

34 enrolled

Dermatologic

Carcinoma, Squamous Cell, Skin Neoplasms

NCT07058012 2026-05-15

EMPIRE

79 enrolled

Colonic Neoplasms

NCT05208944 2026-05-13

THIO Sequenced With Cemiplimab in Advanced NSCLC

227 enrolled

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Carcinoma, Large Cell

NCT05363319 2026-05-13

CEMI-LUNG

Recruiting

500 enrolled

DermatologicHead & NeckSarcoma

Carcinoma, Non-Small-Cell Lung

NCT06568172 2026-05-13

Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer

Phase 3 Suspended

420 enrolled

Eyelid Squamous Cell Carcinoma

NCT07147231 2026-05-13

Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer

Phase 1/2 Recruiting

86 enrolled

Phase 1 Not yet recruiting

Colorectal Neoplasms

NCT07422363 2026-05-13

Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma

30 enrolled

CNSSarcoma

Glioblastoma, Gliosarcoma

NCT05669989 2026-05-11

International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab

70 enrolled

Plasma cell

Multiple Myeloma

NCT05694871 2026-05-11

Testing the Addition of Cemiplimab to Palbociclib for the Treatment of Advanced Dedifferentiated Liposarcoma

Phase 1/2 Active not recruiting

77 enrolled

Sarcoma

Liposarcoma

NCT06162572 2026-05-11

Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)

102 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03564340 2026-05-08

Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

Phase 1/2 Recruiting

890 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT06269133 2026-05-08

Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) Patients

Active not recruiting

1,000 enrolled

Advanced Non-small Cell Lung Cancer

NCT06826768 2026-05-08

A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPC

Phase 1 Recruiting

60 enrolled

Prostatic Neoplasms

NCT01042379 2026-05-06

I-SPY

5,000 enrolled

BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT05557591 2026-05-06

A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)

51 enrolled

Advanced Non-Small Cell Lung Cancer

NCT06205836 2026-05-06

Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer

44 enrolled

Adenocarcinoma, Carcinoma, Colorectal Neoplasms

NCT06246916 2026-05-06

A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

Phase 3 Recruiting

560 enrolled

Dermatologic

Melanoma

NCT06651593 2026-05-06

Phase II Biomarker Study of SAR444881 in Combination With Cemiplimab in Solid Tumors

40 enrolled

Other solid neoplasm

Solid Tumors

NCT06769698 2026-05-06

A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

120 enrolled

Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis, Recurrence

NCT07224022 2026-05-06

NACho

24 enrolled

Colonic Neoplasms

NCT07281768 2026-05-06

Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer

66 enrolled

Adenocarcinoma, Carcinoma, Rectal Neoplasms, Colorectal Neoplasms

NCT06616584 2026-05-05

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

Phase 2/3 Recruiting

378 enrolled

Phase 1/2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07567469 2026-05-05

A Safety and Efficacy Study of Combined Fianlimab + Cemiplimab in Children and Young Adults With Recurrent or Progressive High-Grade Glioma or Posterior Fossa-A Ependymoma

120 enrolled

CNS

Ependymoma, Glioma, Neoplasms, Recurrence

NCT03491683 2026-05-04

INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)

Phase 1/2 Active not recruiting

52 enrolled

CNS

Glioblastoma

NCT05961709 2026-05-04

The Phoenix Trial: Phase II Trial of Cemiplimab for the Non-operative Management of Localized dMMR Colon Cancer

50 enrolled

Colonic Neoplasms

NCT07188896 2026-05-01

A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)

120 enrolled

Carcinoma, Renal Cell

NCT07414992 2026-05-01

A Study of Radiation Therapy and Cemiplimab With or Without Fianlimab In People With Bladder Cancer

44 enrolled